University of Helsinki, Lukupolku 19, 00680, Helsinki, Finland.
World Health Organization, Geneva, Switzerland.
BioDrugs. 2022 May;36(3):359-371. doi: 10.1007/s40259-022-00533-x. Epub 2022 May 21.
The World Health Organization (WHO) guidelines on evaluation of similar biotherapeutic products (SBPs; also called biosimilars) were adopted by the WHO Expert Committee on Biological Standardization (ECBS) in 2009. In 2019, the ECBS considered that a more tailored and potentially reduced clinical data package may be acceptable in cases where this was clearly supported by the available scientific evidence. The goal of this publication is to review the current clinical experience and scientific evidence and to provide an expert perspective for updating the WHO guidelines to provide more flexibility and clarity. As the first step, the relevant guidelines by other regulatory bodies were reviewed in order to identify issues that might help with updating the WHO guidelines. Next, a literature search was conducted for information on the long-term efficacy, safety, and immunogenicity of biosimilars to identify possible long-term problems. Finally, a search for articles concerning the role of clinical studies in the benefit-risk evaluation of biosimilars was conducted. The analysis of other guidelines suggested that the WHO guidelines may need more emphasis on the importance of the state-of-the-art physicochemical and structural comparability exercise and in vitro functional testing. The use of "foreign" reference product will also need clarifications. The value of in vivo toxicological tests in the development of biosimilars is questionable, and the non-clinical part needs revisions accordingly. The concepts of "totality of evidence," "stepwise development," and "residual uncertainty" were applied in the evaluation of the clinical sections of the guideline. The review of long-term safety and efficacy demonstrated the robustness of the current biosimilar development concept. The analysis of the roles of different development phases suggested that the large efficacy, safety, and immunogenicity studies are, in most cases, redundant. The residual uncertainty of safety, immunogenicity, and efficacy of biosimilars that has shaped the current regulatory guidelines is now substantially reduced. This will allow the re-evaluation of the non-clinical and clinical requirements of the current WHO main guideline. The shift of the relative impact of the development phases towards physico-chemical and in vitro functional testing will provide a relief to the manufacturers and new challenges to the regulators.
世界卫生组织(世卫组织)于 2009 年通过了生物类似药(SBPs;也称为生物仿制药)评估指南。2019 年,世卫组织生物标准化专家委员会(ECBS)认为,在现有科学证据明确支持的情况下,临床数据资料包可能可以更具针对性并适当减少。本出版物的目的是审查目前的临床经验和科学证据,并为更新世卫组织指南提供专家意见,以提高其灵活性和清晰度。作为第一步,审查了其他监管机构的相关指南,以确定可能有助于更新世卫组织指南的问题。接下来,进行了文献检索,以获取有关生物类似药长期疗效、安全性和免疫原性的信息,以确定可能存在的长期问题。最后,检索了关于临床研究在生物类似药获益-风险评估中的作用的文章。对其他指南的分析表明,世卫组织指南可能需要更加强调最先进的理化和结构可比性研究以及体外功能测试的重要性。使用“外国”参比产品也需要加以澄清。在生物类似药开发中,体内毒理学试验的价值值得怀疑,因此非临床部分也需要相应修订。“整体证据”、“逐步开发”和“剩余不确定性”的概念应用于指南临床部分的评估中。对长期安全性和疗效的审查证明了当前生物类似药开发概念的稳健性。对不同开发阶段作用的分析表明,在大多数情况下,大型疗效、安全性和免疫原性研究都是多余的。安全性、免疫原性和生物类似药疗效的剩余不确定性已大大降低,这将允许重新评估当前世卫组织主要指南的非临床和临床要求。开发阶段的相对影响向理化和体外功能测试转移将为制造商提供缓解,同时也为监管机构带来新的挑战。